Subsets of Lupus Patients Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib
Objective Baricitinib is a JAK1 inhibitor that showed efficacy in patients with systemic lupus erythematosus (SLE) in a phase 2 study but failed to meet the primary endpoint in phase 3 trials. To understand this discrepancy and identify patients with SLE who are responsive to ba…